Now Playing
Opinion|Videos|December 5, 2024
Unmet Needs in the Management of Patients with Hyperlipidemia
Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP, discusses how maximally tolerated statin therapy often fails to achieve target low-density lipoprotein cholesterol levels in high-risk patients with atherosclerotic cardiovascular disease and share strategies for optimizing adherence, including when to switch therapies to improve patient outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- In your clinical experience, how frequently does maximally tolerated statin therapy fail to lower low-density lipoprotein cholesterol levels below 70 mg/dL in high-risk patients with atherosclerotic cardiovascular disease?
- How about levels below 55 mg/dL?
- Patient adherence to statins is often suboptimal. What are your best methods to optimize adherence?
- In which scenarios do you switch patients’ therapies to optimize adherence?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
Nipah Outbreak in India Poses Low Global Risk Despite Lack of Approved Treatments
3
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
4
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
5